Abstract: This invention relates to methods of treating cancer in a patient need thereof, e.g., in a human subject, comprising determining the level of soluble BCMA (sBCMA) in a sample from the patient, and administering to the patient an effective amount of a BCMA antigen binding protein, thereby treating the cancer in the patient. Also provided are kits for the treatment of cancer comprising a means for determining the level of sBCMA in a sample from a patient.

Abstract: The present disclosure provides diagnostic methods that are relevant to various cancers and which comprise improvements on a BH3 profiling diagnostic method. The methods are relevant for selecting a cancer treatment for a patient, comprising measurement of response to agents that perturb the MCL1 and BFL1 proteins in their function to sequester pro-apoptotic proteins using BH3 profiling of patient cancer cells and inclusion of one or more clinical features of the patient into a predictive algorithm to classify each patient's likelihood of clinical response to one or more cancer treatments that perturb the function of MCL1.

Abstract: The present disclosure provides diagnostic methods that are relevant to various cancers and which comprise improvements on a BH3 profiling diagnostic method.

Abstract: The present disclosure provides diagnostic methods that are relevant to various cancers and which comprise improvements on a BH3 profiling diagnostic method.

Abstract: The present invention relates to diagnostic methods that are relevant to various solid tumor cancers that are not amenable to traditional BIH3 profiling diagnostic methods. In some embodiments, the methods described herein are useful in the evaluation of a patient, for example, for evaluating diagnosis, prognosis, and response to treatment. In various aspects, the present disclosure includes evaluating a solid tumor or cancer. In various embodiments, the evaluation may be selected from diagnosis, prognosis, and response to treatment. In various embodiments, the present disclosure directs the treatment of a cancer patient, including, for example, what type of treatment should be administered or withheld. In some embodiments, the present disclosure includes the measurement of a tumor cell, sample, and/or specimen, including biopsy or surgical specimen samples.